News
-
IP
The patent for the invention, “METHOD FOR PRODUCING DNA-EDITED EUKARYOTIC CELL, AND KIT USED IN SAME,” was issued by the United States Patent and Trademark Office on November 7, 2023.Patent number is 11807869.
-
Alliance
C4U and Healiva have entered into a Strategic Alliance Agreement for medical applications of CRISPR-Cas3 technology.
-
Alliance
C4U enters into Non-Exclusive Sublicense Agreement with Rege Nephro
-
IP
The patent for the invention, “METHOD FOR MANUFACTURING DNA-EDITED EUKARYOTIC CELL, AND KIT USED IN METHOD,” was issued by the Japan Patent Office on 23 June, 2023.
-
Alliance
C4U and Inplanta Innovations enter into Collaborative Research and Alliance Agreement
-
Alliance
C4U Corporation has raised a total of 1.5 billion JPY (approximately $11 million at the then-effective exchange rate) for its Series B financing.
-
Information
Our researcher will give a poster presentation at the Keystone Symposia on Molecular and Cellular Biology “Precision Genome Engineering”, in Whistler, Canada, from March 19-23, 2023.
-
Alliance
C4U and Brain Research Institute, Niigata University have entered into the collaborative research agreement for a novel gene therapy utilizing CRISPR -Cas3 technology.
-
R&D
The paper “Dynamic mechanisms of CRISPR interference by Escherichia coli CRISPR-Cas3” was published in Nature Communications.
-
Alliance
C4U and Sumitomo Dainippon Pharma enter into Collaborative Research and Alliance Agreement